<DOC>
	<DOCNO>NCT02753894</DOCNO>
	<brief_summary>The objective study examine clinical dose range ASP1585 base efficacy , safety , feasibility treatment chronic kidney disease patient hemodialysis hyperphosphatemia .</brief_summary>
	<brief_title>Dose Range-finding Study ASP1585 Chronic Kidney Disease Patients Hemodialysis With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>For preliminary enrollment Patients stable chronic kidney disease receive hemodialysis 3 time week least 12 week ( 84 day ) prior day preliminary enrollment Patients dialysis condition alter ( dialysate calcium concentration , dialyser , dry weight ) within 10 day prior day preliminary enrollment Patients follow dosage administration alter least 28 day prior day preliminary enrollment : phosphate binder , drugs/food phosphate bind action ( include newly start treatment ) If receive vitamin D calcitonin agent , patient dosage administration alter ( include newly start treatment ) least 28 day prior day preliminary enrollment . Patients use cinacalcet hydrochloride least 28 day prior day preliminary enrollment For practical enrollment Patients whose predialysis serum phosphorus level maximum dialysis interval Week 1 washout period ≥8.0 mg/dL &lt; 10.0 mg/dL Week 2 ≥6.0 mg/dL &lt; 10.0 mg/dL Patients continue receive hemodialysis 3 time week day preliminary enrollment Patients dialysis condition alter ( dialysate calcium concentration dialyser ) day preliminary enrollment Patients receive phosphate binder , drugs/food phosphate bind action washout period If receive vitamin D calcitonin agent ( include start new treatment ) day preliminary enrollment , patient dosage administration alter least 28 day prior day preliminary enrollment Patients use cinacalcet hydrochloride day preliminary enrollment For preliminary enrollment Patients history gastrectomy enterectomy ( except appendectomy ) complication dysphagia , ileus , hemorrhagic gastrointestinal lesion Patients severe persistent constipation diarrhoea Patients underwent parathyroid intervention ( parathyroidectomy [ PTx ] , percutaneous ethanol injection therapy [ PEIT ] , etc . ) within 1 year prior day preliminary enrollment Patients fast extreme dietary restriction Patients uncontrollable hypertension ( last 3 measurement value predialysis systolic/diastolic blood pressure day preliminary enrollment ≥180 mmHg ≥120 mmHg , respectively ) Patients severe heart disease ( congestive heart failure [ NYHA cardiac function classification Class III severer ] , history extensive old myocardial infarction , etc . ) patient hospitalize treatment cerebrovascular disease heart disease within 12 week ( 84 day ) prior day preliminary enrollment Patients complication serious hepatic disease ( acute active chronic hepatitis , hepatic cirrhosis , etc . ) Patients history serious drug hypersensitivity , anaphylactic shock Patients history complication malignant tumor ( consider eligible recurrence observe least 5 year ) Patients pregnant , nursing , suspect pregnant , wish become pregnant study period Patients previously receive ASP1585 Patients participate another clinical study postmarketing clinical study ( include medical device ) within 12 week ( 84 day ) prior inform consent For practical enrollment Patients whose predialysis serum phosphorus level maximum dialysis interval Week 1 2 washout period ≥10 mg/dL Patients underwent gastrectomy enterectomy , dysphagia , ileus , hemorrhagic gastrointestinal lesion day preliminary enrollment Patents severe persistent constipation diarrhoea day preliminary enrollment Patients underwent parathyroid intervention ( parathyroidectomy [ PTx ] , percutaneous ethanol injection therapy [ PEIT ] , etc . ) day preliminary enrollment Patients fast extreme dietary restriction day preliminary enrollment Patients uncontrollable hypertension ( two third predialysis systolic/diastolic blood pressure value ≥180 mmHg ≥120 mmHg , respectively , day preliminary enrollment ) Patients severe heart disease ( congestive heart failure [ NYHA cardiac function classification Class III severer ] , etc . ) patient hospitalize treatment cerebrovascular disease heart disease day preliminary enrollment Patients complication impair liver function ( baseline AST ALT 100 IU/L high ) serious hepatic disease ( acute active chronic hepatitis , liver cirrhosis , etc . ) Patients experience serious drug hypersensitivity anaphylactic shock day preliminary enrollment Patients complication malignant tumor Patients find pregnant day preliminary enrollment Patients participate another clinical study postmarketing clinical study ( include medical device ) day inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Dose-finding</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>ASP1585</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>